InvestorsHub Logo
Followers 56
Posts 1134
Boards Moderated 1
Alias Born 01/13/2017

Re: None

Friday, 01/20/2017 8:59:03 AM

Friday, January 20, 2017 8:59:03 AM

Post# of 203914
Revenues, once started, will be dramatic. OWCP is coasting right now, but very soon it will be bringing in money on two fronts. First up is the psoriasis cream, which will be marked in EU and in certain US states. If you read the deals, they show just how savvy the OWCP executive team is. For a share of the profits, the two companies will manufacture, distribute and market the product. It is a genius strategy, and both companies put up $300,000 each for right to be the distributer. If that isn't a total vote of confidence, I don't know what is.

Next is the sublingual tablet. Take a look at the Oct 2016 press release (my bold/underline):

https://www.otcmarkets.com/stock/OWCP/news/OWC-Pharmaceutical-Research-Corp-Completes-Development-of-Its-Medical-Cannabis-Sublingual-Tablet?id=142876&b=y

The technology behind the Tablet is protected and provides for the ingestion of virtually any dosage of medical cannabis with a sublingual delivery mechanism, whereby the compounds are absorbed directly into the patient's blood through oral epithelial tissue. The Tablet also enables physicians to safely and accurately monitor the dosage and treatment of each individual patient, something that is essentially impossible to do for patients who administer cannabis by smoking.

Mr. Turner went on to say, "We are already in discussion with the Ministry of Health here in Israel, and we have been solicited by a number of licensee candidates looking to bring the technology to the States. Of course we will have to pursue the US market on a state by state basis, as regulations allow."



Some people may wonder why pharma companies trade at forward PEs of 20 while biotech firms trade at forward PEs of 110 (http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/pedata.html), the answer is pharma drug patents eventually expire and the products can be sold generically. Biotech patents, like OWCP's proprietary delivery systems via cream, sublingual tablet, and the upcoming nasal spray, never expire. They will be generating money for OWCP indefinitely.